Compounds > N-(3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

Page last updated: 2024-12-11

N-(3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	7066682
CHEMBL ID	1311880
CHEBI ID	92509
SCHEMBL ID	2588694

Synonyms (13)

Synonym
AKOS001795003
MLS000950238
smr000621524
NCGC00186538-02
bdbm50361534
n-(3-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide
HMS2917C23
CHEMBL1311880 ,
SCHEMBL2588694
SR-01000121764-1
sr-01000121764
CHEBI:92509
Q27164239

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
quinolines	A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
USP1 protein, partial	Homo sapiens (human)	Potency	6.3096	0.0316	37.5844	354.8130	AID743255
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	4.4668	0.7079	12.1943	39.8107	AID720542
pyruvate kinase PKM isoform a	Homo sapiens (human)	Potency	2.9075	0.0401	7.4590	31.6228	AID1631; AID1634; AID2533; AID2576
eyes absent homolog 2 isoform a	Homo sapiens (human)	Potency	22.3872	1.1998	14.6419	50.1187	AID488837
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	14.1254	0.0501	27.0736	89.1251	AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Pyruvate kinase PKM	Homo sapiens (human)	EC50 (µMol)	0.2500	0.0005	0.5920	6.0000	AID639784
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Process	via Protein(s)	Taxonomy
programmed cell death	Pyruvate kinase PKM	Homo sapiens (human)
canonical glycolysis	Pyruvate kinase PKM	Homo sapiens (human)
positive regulation of sprouting angiogenesis	Pyruvate kinase PKM	Homo sapiens (human)
positive regulation of cytoplasmic translation	Pyruvate kinase PKM	Homo sapiens (human)
glycolytic process	Pyruvate kinase PKM	Homo sapiens (human)
cellular response to insulin stimulus	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Process	via Protein(s)	Taxonomy
magnesium ion binding	Pyruvate kinase PKM	Homo sapiens (human)
RNA binding	Pyruvate kinase PKM	Homo sapiens (human)
mRNA binding	Pyruvate kinase PKM	Homo sapiens (human)
protein tyrosine kinase activity	Pyruvate kinase PKM	Homo sapiens (human)
pyruvate kinase activity	Pyruvate kinase PKM	Homo sapiens (human)
protein binding	Pyruvate kinase PKM	Homo sapiens (human)
ATP binding	Pyruvate kinase PKM	Homo sapiens (human)
MHC class II protein complex binding	Pyruvate kinase PKM	Homo sapiens (human)
potassium ion binding	Pyruvate kinase PKM	Homo sapiens (human)
cadherin binding	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Process	via Protein(s)	Taxonomy
extracellular region	Pyruvate kinase PKM	Homo sapiens (human)
nucleus	Pyruvate kinase PKM	Homo sapiens (human)
cytoplasm	Pyruvate kinase PKM	Homo sapiens (human)
mitochondrion	Pyruvate kinase PKM	Homo sapiens (human)
rough endoplasmic reticulum	Pyruvate kinase PKM	Homo sapiens (human)
cytosol	Pyruvate kinase PKM	Homo sapiens (human)
cilium	Pyruvate kinase PKM	Homo sapiens (human)
vesicle	Pyruvate kinase PKM	Homo sapiens (human)
secretory granule lumen	Pyruvate kinase PKM	Homo sapiens (human)
collagen-containing extracellular matrix	Pyruvate kinase PKM	Homo sapiens (human)
extracellular exosome	Pyruvate kinase PKM	Homo sapiens (human)
extracellular vesicle	Pyruvate kinase PKM	Homo sapiens (human)
ficolin-1-rich granule lumen	Pyruvate kinase PKM	Homo sapiens (human)
cytoplasm	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID639784	Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639786	Activation of human PKM2 assessed as ATP product formation at 57 uM after 1 hr by luminescent pyruvate-kinase luciferase coupled assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.35 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.30 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
N-(4-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	0	quinolines
N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	0	quinolines
N-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	0	quinolines
6-[(3-methoxyphenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone [no description available]	2.06	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.06	1	0	benzenes; sulfonamide

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0
Benign Neoplasms [description not available]	0	2.06	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.06	1	0